Jaguar Health Reports Decreased Revenue in Q1 2025

Jaguar Health, Inc. announced its financial results for the first quarter of 2025, showing a decrease in net revenue. The company's total revenue for prescription and non-prescription products reached approximately $2.2 million, a 6% decline from Q1 2024 and a 37% drop from Q4 2024. Despite the challenging revenue scenario, Mytesi, one of their key products, experienced a 1.8% increase in prescription volume compared to Q1 2024, though it dipped by 13.5% against Q4 2024.

The company reported a higher net loss of $10.4 million compared to $9.2 million in the same quarter the previous year. Sales and marketing expenses rose by $1.1 million partly due to the commercial launch of Gelclair. Notably, R&D expenses decreased following the conclusion of the Phase 3 OnTarget trial. A positive FDA meeting is anticipated in Q2 2025 based on the trial’s significant results.